Back to Search
HYMAN MUSS, MD
MD
Hematology & Oncology Physician
NPI: 1770665580Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
19270(NC)42-0009296(VT)
Research & Publications (20)
Cancer in the elderly: a societal perspective from the United States.
PMID 19059768·Clin Oncol (R Coll Radiol)·2009
8-other
Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.
PMID 18054880·Lancet Oncol·2007
6-review
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
PMID 17704418·J Clin Oncol·2007
2-rct
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
PMID 15741529·JAMA·2005
4-observational
Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status.
PMID 11773292·J Natl Cancer Inst Monogr·2001
8-other
Clinical research in the older cancer patient.
PMID 10680083·Hematol Oncol Clin North Am·2000
6-review
Adjuvant chemotherapy in older women with early-stage breast cancer.
PMID 19439741·N Engl J Med·2009
4-observational
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
PMID 19204201·J Clin Oncol·2009
3-trial
A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
PMID 19561005·Clin Breast Cancer·2009
6-review
Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
PMID 19037667·Support Care Cancer·2009
3-trial
Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.
PMID 18373191·Breast Cancer Res Treat·2009
8-other
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
PMID 18375893·J Clin Oncol·2008
3-trial
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
PMID 18390970·J Clin Oncol·2008
2-rct
Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
PMID 18483373·Clin Cancer Res·2008
3-trial
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
PMID 18509177·J Clin Oncol·2008
8-other
Extended adjuvant endocrine therapy in breast cancer: current status and future directions.
PMID 18952554·Clin Breast Cancer·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 143 W FRANKLIN ST, SUITE #600
CHAPEL HILL, NC 27516 - Phone
- (919) 966-4131
Quick Facts
- NPI
- 1770665580
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile